Scarica l'app Stockscreener
0.98
2.00%
-0.02
Dopo l'orario di chiusura:
.98
Actinium Pharmaceuticals Inc Borsa (ATNM) Ultime notizie
ATNM Should I Buy - Intellectia AI
Actinium Pharmaceuticals presents expanded ATNM-400 results in NSCLC and prostate cancer - Traders Union
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC - BioWorld News
Actinium presents preclinical data on ATNM-400 for lung cancer - Investing.com UK
Actinium Pharmaceuticals (ATNM) Reveals Promising Preclinical Data for NSCLC Treatment - GuruFocus
Actinium presents preclinical data on ATNM-400 for lung cancer By Investing.com - Investing.com Australia
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer - PR Newswire
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models - PR Newswire
Actinium Pharmaceuticals (ATNM) Appoints New Chief Medical Officer - GuruFocus
Actinium Pharmaceuticals (ATNM) Unveils Key Radiochemistry Findi - GuruFocus
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development - PR Newswire
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates - PR Newswire
Actinium Pharmaceuticals Presents ATNM-400 Program Updates at SNMMI 2026 and Addresses NYSE American Listing Compliance Notice - Minichart
Actinium Pharmaceuticals Advances with Canadian Patent Allowances for ATNM - GuruFocus
Actinium Highlights New ATNM-400 Data Amid Listing Pressure - TipRanks
Actinium Pharmaceuticals, Inc. (ATNM) announced that two patent applications related to its Actimab-a and Iomab-Act projects have been granted by the Canadian Intellectual Property Office. - Bitget
Actinium Pharmaceuticalsreceives two Canadian patent allowances for Actimab-A and Iomab-Act programs - marketscreener.com
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs - PR Newswire
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice – Company AnnouncementFT.com - Financial Times
Actinium Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Actinium Pharmaceuticals (NYSE: ATNM) faces NYSE American equity shortfall and listing risk - Stock Titan
ATNM Stock Price, Quote & Chart | ACTINIUM PHARMACEUTICALS INC (NYSEARCA:ATNM) - ChartMill
Actinium Pharmaceuticals (ATNM): Modest Gain Above Support as Biotech Stock Holds Key LevelRegression Channel - The Legal Advocate
Actinium Pharmaceuticals (ATNM) Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Advances ContinueRevenue Beat Analysis - The Legal Advocate
Actinium Pharmaceuticals (ATNM) Q1 2026 Earnings: Narrower Loss Beats Expectations as Development Pipeline AdvancesEarnings Surprise Report - newsline.com
Actinium (ATNM) Delivers Q1 2026 Beat — EPS $-0.18 vs $-0.24 ExpectedMost Discussed Stocks - Newser
Actinium (ATNM) Falls -2.34% — Watching $1.19 Support 2026-05-15Viral Trade Signals - newser.com
TradingKey - TradingKey
MSN Money - MSN
Actinium: Q1 Earnings Snapshot - 10TV
[10-Q] Actinium Pharmaceuticals, Inc. Quarterly Earnings Report - Stock Titan
Actinium Pharmaceuticals Inc. (ATNM) Stock Price | Live Quotes & Charts | AMEX - StocksToTrade
Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization - Barchart.com
Actinium presents preclinical data on AML drug at AACR meeting By Investing.com - Investing.com India
Actinium Pharmaceuticals (ATNM) Unveils Promising Preclinical Fi - GuruFocus
Actinium Pharmaceuticals (ATNM) Presents Promising Data on Actim - GuruFocus
Actinium presents preclinical data on AML drug at AACR meeting - Investing.com
Actinium Pharmaceuticals presents preclinical data for ATNM-400 - Investing.com
Actinium Pharmaceuticals presents preclinical data for ATNM-400 By Investing.com - Investing.com South Africa
Dr. Electric Explains What Colorado Springs Homeowners Should Check Before Summer Electrical Demand Peaks - Weekly Voice
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting - PR Newswire
SDEV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Targeted Alpha Therapy Market Landscape Report 2026-2030: Clinical Trials Insights on 30 Drugs - GlobeNewswire Inc.
SLS vs ATNM: Which cancer stock has bigger upside ahead of fresh data reveal? - MSN
SLS Vs ATNM: Which Cancer Stock Has Bigger Upside Ahead Of Fresh Data Reveal? - Stocktwits
Actinium (ATNM) Stock: Is It a Strong Buy? (+4.00%) 2026-04-18AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
ATNM Actinium Pharmaceuticals Inc. (Delaware) gains four percent after Q4 2025 results despite slight EPS miss against analyst expectations.Financial Data - newsline.com
What are analysts saying about Actinium (ATNM) Stock | Price at $1.07, Down 0.93%Expert Stock Picks - newser.com
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):